Conferences

PartneringScientific and clinical experts from Vernalis regularly attend international conferences in drug discovery and related areas.

Conferences we have attended / will be attending include:

Partnering

  • 25–27 April 2016, BioTrinity London
  • 6–9 June 2016, BIO San Francisco
  • 13–15 September 2016, BIO Pharm America Boston

Scientific

 2016

  • 13-16 March 2016,  ACS San Diego
  • 19-22 April 2016, CHI Drug Discovery Chemistry, San Diego
  • 12-13 May 2016, GTCBio Drug Discovery, Berlin
  • 7-10 June 2016, 3rd NovAliX Biophysics Conference, Strasbourg
  • 12-13 June 2016, GTC Bio: 2nd Kinase Inhibitors Design & Screening, Berlin
  • 15-16 June 2016, Global Structural Drug Design Summit, Lisbon
  • 12-15 July FBDD Down-Under, Melbourne, Australia
  • 9-10 October 2016, FBLD2016, Cambridge, MA

2017

  • 6-7 March 2017, Drug Discovery, Selectbio, Cambridge, UK

Latest News

Unaudited Interim Results for the six months ended 31 December 2016

Vernalis plc (LSE: VER) today announces its unaudited consolidated results for the six month period ended 31 December 2016. 

Read more ...

At a glance

More information on Vernalis and its pipeline ...

FactsheetNov14 Company fact sheet

Comm thumbnail Explore the pipeline ...

Contact Vernalis

T: 0118 938 0000
F: 0118 938 0001

Contact information
Maps and directions
Contact form

To report SUSPECTED ADVERSE REACTIONS, contact Vernalis Therapeutics, Inc. at 1-855-705-9546 and drugsafety@propharmagroup.com or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch